Free Trial
NASDAQ:ATHA

Athira Pharma (ATHA) Stock Price, News & Analysis

Athira Pharma logo
$4.14 -0.02 (-0.48%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$4.14 0.00 (-0.12%)
As of 10/3/2025 05:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Athira Pharma Stock (NASDAQ:ATHA)

Advanced

Key Stats

Today's Range
$4.08
$4.23
50-Day Range
$3.57
$4.22
52-Week Range
$2.20
$8.26
Volume
20,305 shs
Average Volume
43,940 shs
Market Capitalization
$16.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00
Consensus Rating
Sell

Company Overview

Athira Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
30th Percentile Overall Score

ATHA MarketRank™: 

Athira Pharma scored higher than 30% of companies evaluated by MarketBeat, and ranked 787th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Athira Pharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no buy ratings, no hold ratings, and 1 sell rating.

  • Upside/Downside

    The consensus price target for Athira Pharma is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Athira Pharma has only been the subject of 1 research reports in the past 90 days.

  • Read more about Athira Pharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Athira Pharma are expected to grow in the coming year, from ($2.35) to ($0.82) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Athira Pharma is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Athira Pharma is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Athira Pharma has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Athira Pharma's valuation and earnings.
  • Percentage of Shares Shorted

    2.84% of the float of Athira Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Athira Pharma has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Athira Pharma has recently decreased by 88.60%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Athira Pharma does not currently pay a dividend.

  • Dividend Growth

    Athira Pharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.84% of the float of Athira Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Athira Pharma has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Athira Pharma has recently decreased by 88.60%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Athira Pharma has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Athira Pharma this week, compared to 1 article on an average week.
  • Search Interest

    7 people have searched for ATHA on MarketBeat in the last 30 days.
  • MarketBeat Follows

    Only 1 people have added Athira Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Athira Pharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    22.10% of the stock of Athira Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    57.12% of the stock of Athira Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Athira Pharma's insider trading history.
Receive ATHA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Athira Pharma and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ATHA Stock News Headlines

Athira Pharma (NASDAQ:ATHA) Stock Price Up 9.1% - What's Next?
Trump's Law S.1582: $21T Dollar Revolution Coming
Do you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. If you do…tc pixel
Athira Pharma trading halted, news pending
Athira Pharma, Inc.: Athira Pharma Announces Reverse Stock Split
Athira Pharma Announces Reverse Stock Split
See More Headlines

ATHA Stock Analysis - Frequently Asked Questions

Athira Pharma's stock was trading at $5.8670 at the start of the year. Since then, ATHA shares have decreased by 29.4% and is now trading at $4.14.

Athira Pharma, Inc. (NASDAQ:ATHA) released its quarterly earnings results on Thursday, August, 7th. The company reported ($1.80) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.80).

Athira Pharma's stock reverse split before market open on Thursday, September 18th 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 17th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Athira Pharma (ATHA) raised $160 million in an initial public offering on Friday, September 18th 2020. The company issued 10,000,000 shares at $15.00-$17.00 per share. Goldman Sachs, Jefferies and Stifel acted as the underwriters for the IPO and JMP Securities was co-manager.

Shares of ATHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Athira Pharma investors own include Pfizer (PFE), PayPal (PYPL), Advanced Micro Devices (AMD), Alibaba Group (BABA), Intel (INTC) and Meta Platforms (META).

Company Calendar

Last Earnings
8/07/2025
Today
10/05/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ATHA
CIK
1620463
Fax
N/A
Employees
40
Year Founded
2011

Price Target and Rating

High Price Target
$4.00
Low Price Target
$4.00
Potential Upside/Downside
-3.4%
Consensus Rating
Sell
Rating Score (0-4)
1.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
($15.50)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$96.94 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-139.40%
Return on Assets
-106.84%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.81
Quick Ratio
10.81

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$11.60 per share
Price / Book
0.36

Miscellaneous

Outstanding Shares
3,940,000
Free Float
3,072,000
Market Cap
$16.31 million
Optionable
Optionable
Beta
3.01

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:ATHA) was last updated on 10/5/2025 by MarketBeat.com Staff
From Our Partners